Unripe (top) and ripe (bottom) tomatoes. Regular tomatoes (far left) start out green and turn red when ripe. In contrast, genetically engineered tomatoes assume different shades of red-violet, depending on whether they produce betalains (second from left), pigments called anthocyanins (second from right) or betalains together with anthocyanins (far right)

Weizmann and Hebrew U. (Israel): GMO vegetables and flowers pigments againts cancer

Color in the plant kingdom is not merely a joy to the eye. Colored pigments attract pollinating insects, they protect plants against disease, and...

Read more
Pr Marcelle Machluf, Doyenne de la faculté de bioTechnologie  et de génie alimentaire du Technion (Israël)

Interview of Prof. Marcelle Machluf Technion direct delivery Cancer therapy

Interview of Prof. Marcelle Machluf Technion direct delivery Cancer therap. Prof. Marcelle Machluf of Technion-Israel Institute of Technology’s Faculty of Biotechnology and Food Engineering discussed...

Read more
A g. Dr Fernanda Cerqueira, à d. Prof Varda Shoshan Barmatz

(Français) Cancer, diabète, maladies dégénératives… La mitochondrie, nouvelle cible de traitement à l’Université Ben Gourion

Sorry, this entry is only available in French. For the sake of viewer convenience, the content is shown below in the alternative language. You...

Read more

GENOMIC VISION First R&D DAY, May 10th, Paris, France

Genomic Vision, a biotech company specialized in the development of diagnostic tests for the early detection of cancers and genetic diseases, will host a...

Read more

Tel Aviv University, Hadassah, Sheba: Scientists Discover Mechanism That Causes Cancer Cells to Self-destruct

Many cancer patients struggle with the adverse effects of chemotherapy, still the most prescribed cancer treatment. For patients with pancreatic cancer and other aggressive...

Read more
Au centre en rouge le Dr Revital Rattenbach, CEO de 4PPharma

France-Israel: 4P-Pharma, SATT Aquitaine and Bordeaux University to develop an anti-cancer drug. Video

4P-Pharma has signed an exclusive license agreement with Aquitaine Science Transfert, for the development of a drug targeting pancreatic cancer, triple negative breast cancer...

Read more
(l-r) Yeda CEO Amir Naiberg, Vice President for Technology Transfer Prof. Mudi Sheves, Merck Deputy CEO and Vice Chairman of the Executive Board Stefan Oschmann and Merck Executive board member and Healthcare CEO Belén Garijo

Merck and Weizmann Institute Sign New Framework Agreement on Research Collaboration

Merck, a leading science and technology company, today extended the partnership with Weizmann Institute of Science, Rehovot, Israel, by signing a new framework agreement,...

Read more

Technion (Israel): research is making incredible advances!

Why is it that some tumors worsen quickly, while others stop growing on their own or even shrink? Breakthrough research from the laboratory of...

Read more

Israël Science Info